Insider · CIK 0001484729
A. Rachel Leheny
Files at CALC (CalciMedica, Inc.). First filing Nov 6, 2023, latest Jul 21, 2025.
In brief
A. Rachel Leheny files SEC Form 4 as CEO, director and 10% owner at CALC (CalciMedica, Inc.). Since Nov 6, 2023, A. Rachel Leheny has reported 6 open-market buys worth $113k and 0 open-market sells worth $0, the latest filed on Jul 21, 2025.
After A. Rachel Leheny's past buys, the stock beat the S&P 500 by a median 36.4% over six months (n = 3), and 67% of those buys were ahead of the index at six months. InsiderTell labels that a strong record.
The newest scored trade: bought $3,400 of CALC on Jul 21, 2025, filed Jul 21, 2025, scored 59 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CALC: CalciMedica, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | CalciMedica, Inc. | $3,400 1,000 shares | +40% | +144% from low-30% from high | |
| 56Moderate | CalciMedica, Inc. | $6,175 2,500 shares | - | +62% from low-54% from high | |
| 51Moderate | CalciMedica, Inc. | $75k 20,000 shares | +18% | - | |
| 66Notable | CalciMedica, Inc. | $6,680 2,000 shares | +12% | +85% from low-44% from high | |
| 66Notable | CalciMedica, Inc. | $7,615 2,440 shares | +17% | +82% from low-45% from high | |
| 68Notable | CalciMedica, Inc. | $14k 5,000 shares | +53% | +62% from low-51% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | CALC CalciMedica, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +360,000 | $0.00 | $0 | 360,000 | 15 d ago |
| Aug 19, 2026 | CALC CalciMedica, Inc. | AGrant or award Warrantderivative | +186,729 | $0.00 | $0 | 186,729 | Aug 21, 2026 |
| Aug 19, 2026 | CALC CalciMedica, Inc. | AGrant or award Warrantderivative | +186,729 | $0.00 | $0 | 186,729 | Aug 21, 2026 |
| Jun 25, 2026 | CALC CalciMedica, Inc. | AGrant or award Common Stock | +186,729 | $0.80 | $150k | 317,655 | Jun 29, 2026 |
| Apr 5, 2025 | CALC CalciMedica, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +148,482 | $0.00 | $0 | 148,482 | Apr 7, 2026 |
| Jul 21, 2025 | CALC CalciMedica, Inc. | POpen-market purchase Common Stockindirect: By Scheibler-Leheny Family Living Trust | +1,000 | $3.40 | $3,400 | 3,500 | Jul 21, 2025 |
| Jul 14, 2025 | CALC CalciMedica, Inc. | POpen-market purchase Common Stockindirect: By Scheibler-Leheny Family Living Trust | +2,500 | $2.47 | $6,175 | 2,500 | Jul 15, 2025 |
| Jun 24, 2025 | CALC CalciMedica, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +77,625 | $0.00 | $0 | 77,625 | Jun 26, 2025 |
| Apr 23, 2025 | CALC CalciMedica, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +285,000 | $0.00 | $0 | 285,000 | Apr 25, 2025 |
| Nov 1, 2024 | CALC CalciMedica, Inc. | POpen-market purchase Common Stock | +20,000 | $3.75 | $75k | 130,926 | Nov 1, 2024 |
| Nov 7, 2023 | CALC CalciMedica, Inc. | POpen-market purchase Common Stock | +2,000 | $3.34 | $6,680 | 18,840 | Nov 8, 2023 |
| Nov 6, 2023 | CALC CalciMedica, Inc. | POpen-market purchase Common Stock | +2,440 | $3.12 | $7,615 | 16,840 | Nov 7, 2023 |
| Nov 3, 2023 | CALC CalciMedica, Inc. | POpen-market purchase Common Stock | +5,000 | $2.85 | $14k | 14,400 | Nov 6, 2023 |
Questions about A. Rachel Leheny
Answered from the filings on this page, as of the latest one.
Is A. Rachel Leheny buying or selling?
Not in the last 12 months. A. Rachel Leheny's latest open-market trade on SEC Form 4 was bought $3,400 of CALC on Jul 21, 2025.
How did A. Rachel Leheny's past buys perform?
Measured from the first close after each filing, the stock beat the S&P 500 by a median 36.4% over six months across 3 past buys, with 67% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does A. Rachel Leheny file Form 4?
A. Rachel Leheny has filed Form 4 at CALC (CalciMedica, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.